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Abstract
Background: Lymphatic filariasis (LF) is endemic in Myanmar and targeted for elimination. To highlight the
National Programme to Eliminate Lymphatic Filariasis (NPELF) progress between 2000 and 2014, this paper
describes the geographical distribution of LF, the scale-up and impact of mass drug administration (MDA)
implementation, and the first evidence of the decline in transmission in five districts.
Methods: The LF distribution was determined by mapping historical and baseline prevalence data collected by
NPELF. Data on the MDA implementation, reported coverage rates and sentinel site surveillance were summarized.
A statistical model was developed from the available prevalence data to predict prevalence at township level by
year of measurement. Transmission assessment survey (TAS) methods, measuring antigenemia (Ag) prevalence in
children, were used to determine whether prevalence was below a level where recrudescence is unlikely to occur.
Results: The highest baseline LF prevalence was found in the Central Valley region. The MDA implementation
activities scaled up to cover 45 districts, representing the majority of the endemic population, with drug coverage
rates ranging from 60.0% to 98.5%. Challenges related to drug supply and local conflict were reported, and
interrupted MDA in some districts. Overall, significant reductions in LF prevalence were found, especially after the
first 2 to 3 rounds of MDA, which was supported by the corresponding model. The TAS activities in five districts
found only two Ag positive children, resulting in all districts passing the critical threshold.
Conclusion: Overall, the Myanmar NPELF has made positive steps forward in the elimination of LF despite several
challenges, however, it needs to maintain momentum, drawing on international stakeholder support, to aim
towards the national and global goals of elimination.
Keywords: Lymphatic filariasis, Elephantiasis, Wuchereria bancrofti, Neglected tropical diseases, Mass drug
administration, Transmission assessment surveys, Surveillance, Myanmar
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Background
Lymphatic filariasis (LF) is a major public health prob-
lem in tropical and sub-tropical countries due to the
painful, disabling and disfiguring clinical conditions as-
sociated with chronic infection [1, 2]. The disease is
caused by infection with filarial worms and transmitted
by a range of mosquito species. In humans, the infective
filarial larvae target the lymphatic system, grow to be-
come adult worms and reproduce causing conditions
such as lymphoedema (swelling of arms, legs or breasts),
and hydrocoele (scrotal swelling) in men [3, 4]. The
South-East Asia region accounts for the highest burden
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of disease in the world [5–7], and many countries
adopted the strategy of the Global Program to Eliminate
Lymphatic Filariasis (GPELF) which comprises the main
goals of i) interrupting transmission through at least five
annual rounds of mass drug administration (MDA) with
65% coverage of total population, and ii) alleviating suf-
fering through morbidity management and disability
prevention (MMDP) through the provision of a package
of care to manage lymphedema and hydrocoele within
primary health care systems [8].
Myanmar, formerly known as Burma, is one of the
most endemic countries in South-East Asia, with a high
LF prevalence, where the disease is caused by the para-
site Wuchereria bancrofti and transmitted by the mos-
quito Culex quinquefasciatus [9, 10]. Like many other
countries in the region, Myanmar has a long history of
filarial endemicity, with high infection prevalence levels
in several foci [7, 9, 10]. The Myanmar government
therefore responded to the new GPELF programme, and
developed the National Programme to Eliminate Lymph-
atic Filariasis (NPELF) in 2000. The Myanmar NPELF
drew on the historical evidence, national data and map-
ping studies conducted in the late 1990s to demarcate
the endemic districts of the country [11]. The peninsular
and central inland areas were found to be most endemic
with an estimated 41 million people (~ 80% of total
population) to be at risk of infection in 45 districts.
The initial primary focus of Myanmar NPELF was to
interrupt transmission by reducing prevalence rates
through MDA using two anti-filarial drugs; diethylcar-
bamazine (DEC) and albendazole. Over the past 15 year,
the NPELF has been up-scaling and down-scaling pro-
grammatic activities, including developing a National LF
elimination plan for the WHO in 2000, starting MDA
implementation in 2001 and reaching 43 districts in
2013, conducting ongoing sentinel site surveillance since
2000, and implementing the first surveys to show evi-
dence of impact and reductions in prevalence in 2008
and 2014 using standard World Health Organization
(WHO) guidelines [12–14]. Overall, key steps forward
have been made, despite several challenges related to the
availability of funding, and ready access to the drug
DEC. To highlight the programmatic activities in
Myanmar, this paper describes and maps the geograph-
ical distribution of LF, outlines the progress and impact
of programmatic activities, models the decline in preva-
lence, and highlights the first evidence that prevalence
has been lowered to an extent where transmission is
likely to be no longer sustainable in five districts.
Methods
Study area
Myanmar is a lower middle income tropical country,
and divided into seven states, and seven regions with a
capital NayPyiTaw Union Territory established in 2005
(Fig. 1a). These 15 administrative areas are further orga-
nized into districts, townships, towns, cities, wards,
village-tracts (groups of adjacent villages) and villages.
The latest census data in 2014 indicated that Myanmar
has a population of 51.5 million, with a population dens-
ity of 75 per square kilometre, and more than one third
of the population living in urban areas [15]. Topograph-
ically, there are three distinct regions, which include the
Western Hill Region, Eastern Hill Region and the Cen-
tral Valley Region dominated by the Ayeyarwady basin
with low elevation levels.
The NPELF is part of the Ministry of Health and
Sports (MoHS) and responsible for the MDA imple-
mentation and MMDP activities across the country
[16]. In 2000, Myanmar had a total of 65 districts,
which the NPELF continues to use for programmatic
purposes, despite the recent changes in administrative
boundaries to form 74 districts in 2014. The MoHS
delivers the preventive and curative health services at
all levels, including the LF Programme. Each sub-
rural health centre provides health-care services to a
cluster of five to ten villages, which have health vol-
unteers and who also assist with the LF MDA activ-
ities as community drug distributors.
Geographical distribution of LF
The endemicity status of each of the 65 districts in
Myanmar in 2000, was based on collated historical data,
national reports and rapid prevalence mapping surveys
conducted in 19 districts as part of a WHO multi-
country study [11]. Based on this, 45 districts out of the
65 districts were defined as endemic. The most extensive
mapping survey conducted by the WHO included a total
of 70 randomly selected townships in the 19 districts.
The prevalence of antigenaemia (Ag) was determined
using the immuno-chromatographic test (ICT) card
(BinaxNOW Filariasis, Alere Inc., Scarborough, ME)
antigen detection kits from 100 voluntary participants
from randomly selected wards and households, which
included everyone in each household except the very ill
and those people who were not present at the time of
survey.
To highlight the endemic distribution across the
country before the scale up of MDA related activities,
the WHO prevalence point data were re-mapped
across the 45 endemic districts by importing the ori-
ginal map and digitizing the points using a standard
point feature tool in the geographical information sys-
tem software ArcGIS 10 (ESRI, Redlands, CA). The
Global Digital Elevation Model (ETOPO2) was used
as a base map, which was available from ESRI,
Redlands, CA.
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MDA implementation and sentinel sites
To describe the progress and impact of activities related
to the decline in transmission, data on the MDA imple-
mentation, reported coverage and sentinel site surveil-
lance (including randomly selected spot check sites)
were summarised. The MDA implementation activities
were conducted in accordance with the GPELF strategy
where each district, also known as the implementation
unit (IU), is required to conduct at least five rounds of
MDA, with > 65% coverage rate of the entire population
[13]. MDA is community-based and implemented using
the directly observed treatment practice via a door-to-
door or booth distribution by community volunteers,
once a year over the period of a week. The main social
mobilization activities implemented in communities be-
fore MDA included televised media, radio broadcasting,
health talks in the community by programme staff and
basic health staff (i.e. health assistants, midwives, trained
nurses), and the distribution of pamphlets with the as-
sistance from civil society organizations and local au-
thorities. A protocol was developed on how to report
and respond to a range of adverse reactions before the
Fig. 1 Map of administrative units and distribution of LF endemicity before intervention. Note: (a). State and Region abbreviations: Kachin (KC);
Sagaing (SA), Chin (CH), Shan (SH), Mandalay (ML), Magway (MG), Rakhine (RA), Ayeyarwady (AY), Yangon (YA), Bago (BA), Kayah (KH), Kayin (KN),
Mon (MO), Tanintharyi (TN), (b) Endemic districts, (c) Prevalence based on antigenaemia (Ag) determined using the immuno-chromatographic test
(ICT) card (BinaxNOW Filariasis, Alere Inc.,) kits. d Prevalence based on microfilaria (Mf) survey data
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start of the MDA advocacy, with the basic health staff
trained on the procedures.
The monitoring and evaluation of the programme was
conducted through regular sentinel and spot check site
surveillance at township level. These field data were ana-
lysed to help assess the impact before- during- after
MDA implementation activities. Standard surveillance
involved selecting two sites (villages) per IU, with be-
tween 300 to 500 people (including all ages ≥2 years of
age), selected for assessment of infection by examining
night bloods slides for microfilaria (Mf) as per standard
guidelines [13]. The blood smears were processed and
examined in each IU (district) headquarters. The data
were then sent to the central level, where all the data
were maintained in registers and examined at township
level. All baseline sentinel site prevalence data were
mapped by Township geographical boundary using the
software ArcGIS 10 (ESRI, Redland, CA).
Modelling the impact of MDA on prevalence
To better understand the reductions in prevalence asso-
ciated with MDA, a statistical model was developed to
predict the change in Mf prevalence in a township since
the most recent assessment of prevalence, which varied
by site. This most recent Mf value was therefore referred
to below as the “most recent Mf value”. Data were fil-
tered to include only townships for which both a base-
line Mf value (i.e. measurement taken prior to any
MDA), and at least one later sentinel and/or spot check
Mf value were available. Where there were multiple Mf
values recorded at the same township in the same a year,
a mean value was taken and used. Variables considered
for the model included the baseline Mf prevalence value,
the most recent Mf value (this may have been either a
baseline Mf prevalence value or the results of a post-
baseline programmatic survey), the number of MDA
rounds undertaken since the beginning of the MDA
programme, and the number of MDA rounds and years
since the most recent Mf value was collected. Also con-
sidered were calculated variables that attempted to
quantify the fragmented nature of the MDA programme;
for example, the number of MDAs since the most recent
Mf value divided by the number of years over which these
MDAs has been administered. Also, the total number
of MDAs since the beginning of the MDA
programme divided by the number of years over,
which the programme was administered. Finally, the
maximum and mean number of years between MDAs,
both since the start of the programme and since the
most recent Mf value.
First, all Mf values were transformed using log10(x + 1)
due to asymmetry observed in qq plot when untrans-
formed data was modelled. A number of other transfor-
mations were also considered. A Generalized Linear
Model (GLM, function ‘glm’) within the R statistical
environment (R Development Core Team, 2012) was
then used to predict the average Mf values for each
township in a year.
The parsimony protocol outlined by Crawley [17] was
used to simplify the model by removing any redundant
variables and producing the Minimum Adequate Model
(MAM), i.e. non-significant values and interaction terms
were removed sequentially from the highest order inter-
actions downwards. At each step, the significance of de-
leted items was assessed using analysis of variance using
the AIC statistic.
Interruption of transmission
The transmission assessment survey (TAS) is a standar-
dised decision-making tool developed and recommended
by the WHO [13], and was used to determine the de-
cline in transmission in 2014 in five districts from three
regions, including the Magway Region (Minbu District),
Sagaing Region (Kathur, Kalay, Tamu Districts), and
Mandalay Region (Pyin Oolwin District). Prior to stop-
ping MDA, each district had at least five effective rounds
of MDA, showed evidence of > 65% coverage rates, and
demonstrated significant reduction in Ag (< 2%) and Mf
(< 1%) prevalence rates in all sites.
The Kathur, Kalay and Tamu Districts stopped MDA
in late 2007, and were assessed for the decline in trans-
mission using cluster surveys in 2008 according to
WHO guidelines at the time. Therefore, the TAS surveys
conducted in 2014 were considered to be the second
TAS or “TAS 2” for these three districts. The results of
the first cluster surveys or “TAS 1” from the 2008 sur-
veys, and the results from TAS 2 in 2014 were presented
for these three districts.
The TAS survey design was dependent upon factors
such as the net primary school rate in each evaluation
unit (EU), the target population size, school enrolment,
number of schools, mosquito vector type and parasite
species. The TAS Survey Sample Builder was used to
automate the calculations of the sample design, size, in-
tervals and critical cut-off values. The rapid ICT Binax
NOW Filariasis (Alere Inc., Scarborough, ME) was used
to detect circulating filarial antigen (CFA) in the chil-
dren, and validated with a positive control prior to the
commencement of the survey.
Results
Distribution of LF
The WHO LF prevalence survey found filarial antigen
ranged from 0% to > 25%. These data were analysed
spatially to provide an estimated prevalence of filarial
antigen for each district, which highlighted the major fil-
arial focus in the central region of the country. Based on
this national reports and historical data, the NPELF
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defined the 45 endemic IUs (districts) that required
MDA, which were predominately in the lowland areas in
the Central Valley Region (Fig. 1b and c).
The baseline Mf sentinel site prevalence for each IU
was conducted prior to MDA implementation. Sentinel
sites were conducted in a step-wise manner over a
13 year period between 2001 and 2013. Table 1 summa-
rises the MDA and Mf sentinel site information for en-
demic IUs in each region. All baseline sentinel site
prevalence data were mapped by township geographical
boundary, which highlighted similar endemicity patterns
in the Central Valley Region (Fig. 1d).
The Mf baseline average rates were highest in Sagaing
(7.9%), Mandalay (5.2%) and Magway (3.6%) Regions
with the highest rates recorded in the districts of Shwe
Bo (15.1%), Kyauk Se (14.7%) and Pakokku (9.1%) in
2002, 2003 and 2002, respectively. Overall the Mf base-
line average rates were lowest in the districts of Ayeya-
waddy (0.5%), Kayin (0.002%) and Tanintharyi (0.5%)
Regions with the highest Mf rates recorded in Pathein
(2.4%), Myawaddy (0.1%) and Dawei (1.8%) in 2004,
2012 and 2008, respectively. See Additional file 2 for
baseline sentinel site prevalence data.
MDA implementation
The first MDA was implemented in two IUs viz., Mag-
way and Theyet Districts in the Magway Region in 2001
(Fig. 2). MDA was extended to 10 IUs across the Mag-
way and Sagaing Regions in 2002, and then to 22 IUs in
2004, representing approximately 48% geographical
coverage. The majority of these MDA IUs had a rela-
tively higher burden of LF. The NPELF aimed to imple-
ment MDA uninterruptedly, however, no MDA took
place in the years 2005 and 2008 due to delays in DEC
supplies from the donors. Further, in the Mandalay Re-
gion, seven IUs had MDA interrupted twice over the
study period; in 2006 due to incidence of serious adverse
reactions during the preceding MDAs, and in 2010 due
to DEC supply constraints. The adverse reactions ob-
served during 2001–2004 after the initial MDAs were
conducted in Magway Region included giddiness, head-
aches, nausea, rashes, fever, urticaria and vomiting. This
is the only data on adverse reactions available to present,
and it is recognized the reporting system needs to be
strengthened.
The expansion of MDA activities did not take place
until 2013. Considerable efforts were made to extend the
MDA programme to cover all endemic IUs in 2011 and
2012. However, the NPELF could not scale up due to the
lack of funding, need for many resources (e.g. training of
basic health staff, advocacy materials), continued prob-
lems in procuring adequate quantities of DEC, as well as
security related issues in the two endemic districts of
Kachin State. No MDA was conducted in 2012.
Table 1 Summary of regional/provincial endemic districts, MDA start dates and sentinel site prevalence
Region/
Province
Endemic Districts
(Implementation Unit – IUs)
Year of MDA
Start
Year of
Baseline
Sentinel Site
Mfa Baseline
Average
(no. sites)
Mf
Baseline
Range
Mf b3–5 MDA
Round Average
(no. sites)
Mf b > 5 MDA
Round Average
(no. sites)
Magway Magway, Thayet, Minbu, Pakoku, 2001–2002 2001–2002 3.2 (n = 9) 0.2–9.1 2.3 (n = 21) 1.2 (n = 29)
Sagaing Sagaing, Shwe Bo, Monywa, Kathur,
Kalay, Tamu,
2002 2002 4.7 (n = 11) 0–15.1 2.8 (n = 12) 1.2 (n = 43)
Chin Paletwa 2004 2003 1.5 (n = 2) 1.4–1.6 0.2 (n = 2) -
Mandalay Mandalay, Pyin Oo Lwin, Kyauk Se,
Yamethin, Myin Gyan, Meikhtilar,
Nyaung Oo
2004 2003 5.2 (n = 14) 0.2–14.7 - 2.3 (n = 20)
Nay pyi taw Nay pyi taw 2013 2011 1.9 (n = 1) 1.9 - -
Rakhine Sittwe, Maungdaw, Kyauk Phyu,
Thandwe
2004 2003–2004 3.0 (n = 6) 0–12.6 0.6 (n = 13)
Ayeyarwaddy Pathein, Hantada, Myaungmya,
Phyarpone. Maubin
2013 2002–2013 0.5 (n = 12) 0–2.4 - -
Bago Bago, Thanung Ngu, Tharyawaddy,
Pyay
2013 2005–2013 0.7 (n = 10) 0–2.8 - -
Kayin Hpaan, Kawkareik, Myawaddy 2013 2013 0.002 (n = 5) 0–0.1 - -
Mon Mawlamying, Thaton 2013 2004–2013 1.8 (n = 4) 0.8–3.2 - -
Tanintharyi Dawei, Myeik, Kawthaung 2013 2004–2013 0.5 (n = 8) 0–1.8 - -
Yangon Yangon North, Yangon South,
Yangon East, Yangon West
2013 2004–2013 0.1 (n = 8) 0–0.4 - -
aMf average based on the total number of sites (in brackets) across the endemic districts. At each site between 300 and 500 people tested. Some sites were
tested multiple years before MDA started
bMf based on both sentinel sites and spot check sites based on number of sites (in brackets). At each site between 300 and 500 people tested
Mf: microfilaria
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However, in 2013, a major increase in coverage was fi-
nally reached with support from Sanofi Pasteur, WHO
and the Global Network for NTDs for supply of DEC
and operational costs. This up scaling of MDA resulted
in a further 21 IUs receiving treatment in 2013, which co-
incided with the down scaling of MDA in 2 IUs (Minbu
and Pyin Oo Lwin Districts) as they reached the require-
ments for TAS, and a further 4 IUs from Rakhine State
temporarily stopping MDA due to security related issues.
Additional file 3 summarises the scale up and scale down
of MDA related activities between 2001 and 2014.
Overall, the reported treatment coverage i.e. the cover-
age calculated for each IU on the basis of reports sent
from lower level units (townships, villages) was high,
ranging from 68.7% to 98.5% of the IU’s entire popula-
tion (Table 2). A cross-sectional evaluation of the
Fig. 2 Programme MDA up scale and down scale between 2001 and 2014
Table 2 Summary of population and reported treatment coverage rates 2001–2014
Year No. of
regions
No. of
districts
Total population
covered
Population which
ingested drugs
Reported Treatment coverage
Overall Range among districts
2001 1 2 1 939 964 1 803 306 93 -
2002 2 10 8 634 179 7 474 094 95.7 93.2–98.5
2004 5 22 17 929 178 15 838 896 82.6 80.1–94.3
2005 - - No MDA No MDA - -
2006 4 15 11 868 901 10 761 777 90.7 79.5–94.1
2007 5 22 20 000 250 18 397 240 91.9 83.4–93.9
2008 - - No MDA No MDA - -
2009 5 19 17 702 845 15 790 286 89.2 85.5–96.4
2010 4 12 10 035 458 9 002 092 89.7 82.7–95.4
2011 5 19 1 7031 636 15 429 100 90.5 85.8–93.4
2012 - - No MDA No MDA - -
2013 7 36 35 488 298 30 313 249 85.4 68.7–93.8
2014 7 37 36 407 716 31 121 035 85.5 74.8–93.7
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treatment coverage conducted by a team within the De-
partment of Health in randomly selected townships in
2013, found that coverage rates ranged from 60% to
97.4% across 19 IUs, and reflected reported coverage
rates in each corresponding IU. Of those people who
were eligible, but did not take the drug, the main rea-
sons were that they were absent at the time of MDA,
or had refused to take the drugs related to negative
rumours regarding MDA.
Impact of MDA on field collected prevalence data
(baseline and sentinel/spot check sites)
The field collected baseline data varied significantly be-
tween 15.1% to zero in 46 townships across the country.
Figure 3a highlights the prevalence trends by the num-
ber of MDA rounds. All but two townships displayed a
significant reduction in prevalence over the 13 years for
which data was available, especially after two to three
MDA rounds where the prevalence ranged from 0 to
8.8%. The two townships, Amapura and Pakokku,
which reported a rise in prevalence at spot check sites
(outliers) were removed so that general trends could bet-
ter be examined. This resulted in 138 individual Mf site
values included in further analysis, and showed that the
prevalence after two to three MDA rounds was signifi-
cantly reduced, and ranged from 0 to 5.9%.
Modelling the impact of MDA on prevalence
The townships for which sentinel site and spot check
prevalence data were available received between 0 and
12 rounds of MDA. A model predicting the Mf preva-
lence in a township in a year from the most recent as-
sessment of Mf prevalence at the same township was
produced. After the removal of redundant terms, the
model consisted of two coefficients (Fig. 3b; Table 3).
The most significant coefficient, was an interaction term
consisting of two predictor variables (the most recently
collected Mf prevalence (log + 1) and the number of
MDAs administered since that Mf prevalence data were
collected (log + 1). The second most significant coeffi-
cient was the baseline prevalence (log + 1). Together,
this demonstrates that whilst the number of rounds of
MDA is the most important predictor, the underlying
conditions reflected by the baseline figure also affects
the results, i.e. two rounds of MDA in a high baseline
area will not reduce prevalence as much as two rounds
of MDA in a low baselines area, even if the most recent
Mf value in the two areas is the same. Surprisingly, the
covariates that described the fragmented nature of the
MDA (i.e. the number of missed MDA years) did not
feature in the MAM. That is, they did not significantly
improve the fit of the model. This may be due to the
small number of data points available.
The model unexpectedly predicted an increase in
prevalence if there were more rounds of MDA between
measurements of prevalence. However, this appears to
be an artifact of the MDA administration; prevalence
data were usually collected after every two MDA rounds
but were collected after 3 rounds of MDA in Mandalay.
The model shows that three rounds of MDA in Manda-
lay had less effect on prevalence than two rounds of
MDA elsewhere; therefore suggesting that in Mandalay
specifically, the MDAs were less effective.
The modelled data shown in Fig. 3b clearly reflects the
same prevalence trend as the field collected data. The
initial two MDA rounds produced a significant reduc-
tion in prevalence which was followed by a much
smaller reduction in subsequent MDA rounds, with
prevalence levelling out. The models suggest a similar
trend, for example an area with 30% baseline prevalence,
drops to 6.5% after the first two MDA rounds indicating
Fig. 3 Sentinel and spot check data and modelled distributions by number of MDA rounds. (a) Township data (b) Modelled data. Note. Township
data includes all points from all sentinel sites and modelled data include selected sites
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a reduction of 78%. The next two MDA rounds reduce
further, but less dramatically, to 3.5%, and two further
MDA rounds reduce prevalence to 2.8%. For sites with a
baseline of 15%, the effect of the first two MDA rounds
is a 73% reduction to 3.9% prevalence (next two MDA
rounds reduce prevalence to 2.3%, with little further ef-
fect after four MDA rounds). For areas with a baseline
of 7%, the effect of the first two rounds of MDA is a
69% reduction to a prevalence of 2.2% (next two MDA
rounds reduce to 1.4% prevalence, with little effect after
four MDA rounds).
Decline in transmission
In 2008, the first cluster surveys or “TAS 1” for the
Kalay, Kathar and Tamu Districts found no ICT positive
children among the 2269, 3003, and 3085 tested across
16, 31, and 25 schools respectively. Further details of the
schools surveyed are in Additional files 4, 5, and 6.
In 2014, the pre-TAS assessments indicated that all
five IUs had sufficient number of MDA rounds, and high
reported treatment coverage rates of > 85%. Based on
the population size and school enrolment rates of > 90%,
school-based surveys were conducted in each IUs, which
were evaluated as EUs, with sample sizes of between
1556 to 1548 children across 30 to 52 schools, and
critical cut-off of 18 positive children calculated for all
EUs (Table 4).
The field activities involved 5 to 7 teams consisting of
three people each: supervisor, data collector and a tech-
nician. All team members were trained per the TAS
guidelines by a Central and Regional Team leader. The
Township Medical Officer was responsible for informing
and coordinating activities with the Township Education
Department, and Headmasters of the selected school be-
fore the survey. The Headmaster of each school pro-
vided an official class register and all eligible children
were identified for selection. For each selected child,
their name, sex, age, and grade was recorded and 100 μl
of blood collected for ICT. No child refused to partici-
pate in the survey.
The TAS 1 results for Minbu and Pyin Oo Lwin EUs
found 1 positive child, and the TAS 2 results for Kalay,
Kathar and Tamu EUs found 1 positive child (Table 4).
These results resulted in all EUs being under the critical
cut-off and passing TAS. The two positive children were
treated and the parents and relative Township Medical
Officer informed for further monitoring as required.
Discussion
Overall good programmatic progress has been made by the
Myanmar NPELF with the successful scale up of MDA
Table 3 Minimal Adequate Model (MAM) predicting prevalence at Township level from prevalence previously measured and
number rounds MDAs
Coefficients: Estimate Std. Error t value Pr(>|t|)
(Intercept) - 0.05012 0.03641 - 1.377 0.172
logBaselineMf 0.27098 0.05263 5.149 1.77e - 06
logPreviousMf: logMDAsSincePreviousMf 0.73239 0.11677 6.272 1.59e - 08
Residual standard error: 0.1507 on 82 degrees of freedom
Multiple R-squared: 0.6162, Adjusted R-squared: 0.6069
F-statistic: 65.84 on 2 and 82 DF, P-value < 2.2e - 16
Table 4 Summary of IU populations, MDA and TAS characteristics
Population and MDA TAS
Districts Total Pop. MDA Rounds
& Years
MDA Coverage
Range
No. 6–7 aged
Children
No.
Schools
Total Sample
Size
No. Schools
Tested
Children
Absent %
No. ICT
Positive
Minbu TAS 1 689 965 10 MDAs
2002–2014
86–94% 27 252 759 1556 52 2.3% 1
Pyin Oolwin
TAS 1
851 945 6 MDAs
2004–2014
85–99% 32 529 634 1556 36 0.2% 0
Kalay TAS 2 487 762 5 MDAs
2002–2007
85–98% 24 461 387 1556 30 0.7% 0
Kathar TAS 2 819 281 5 MDAs
2002–2007
92–100% 34 090 1077 1556 58 0.4% 1
Tamu TAS 2 105 100 5 MDA
2002–2007
92–100% 17 155 77 1548 30 0% 0
Note. Details of MDA years available in Additional file 3
IU: Implementation Unit
MDA: Mass drug administration
TAS: Transmission assessment survey
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implementation, widespread significant reductions in
prevalence, and the initiation of post-MDA surveillance ac-
tivities in five districts. This national overview extends
the findings from four endemic states/regions by Win et al.,
and highlights that progress has been achieved despite
some challenges in obtaining regular funding and support
from international partners and stakeholders, reports of
side-effects during MDA, internal security issues, and diffi-
culties in obtaining the drug DEC. The progress to-date
may be attributed to several factors identified as determi-
nants of LF programme success as noted in other countries
[18, 19] including the i) general low transmission levels
found at baseline with the majority of Mf rates < 15%;
ii) MDA regime of albendazole and DEC which is consid-
ered a highly effective combination against the
parasite W. bancrofti; and iii) good health system infra-
structure, administration and training. It is also likely that
this widespread MDA coverage with albendazole for LF
has impacted on soil transmitted helminths (STH) infec-
tion rates, which will be beneficial to the STH MDA
programme and should be taken into account [20].
Notwithstanding these positive steps forward, the
NPELF will face some challenges to complete all pro-
grammatic activities by the GPELF elimination goal of
2020 [21, 22]. It will require pro-active interaction with
drug donors to ensure steady DEC supply. International
collaboration and support may be more achievable now
with the changed political situation in country [23]. This
may help to address any challenges that arise and main-
tain the momentum of the programme. The NPELF is at
crucial stage now in terms of undertaking multiple activ-
ities in as many as 45 districts. Hence, more technical
and financial support from international partners and
stakeholders is key to its future success.
Importantly, MDA implementation was initially fo-
cused in high transmission areas, and the programme
was able to demonstrate that the most significant reduc-
tions occurred after 2 to 3 rounds of MDA. This trans-
mission reduction pattern is consistent with other
studies in the South-East Asian Region and elsewhere
[19, 24–27], and is in agreement with the predicted
model presented in this paper. The model confirms that
LF prevalence reduces with number of MDAs. However,
the effect of each subsequent MDA is less than the one
before, and also dependent on the initial prevalence rate.
Notably, after a number of MDAs, the prevalence
reaches an asymptote i.e. levels out to a point, that was
proportional to the initial prevalence rate. This suggests
that, whilst in low endemic areas MDA may be sufficient
to reach elimination, in higher endemic areas, reducing
the transmission levels to zero may prove difficult and
the current MDA strategy would potentially benefit
from supplementary interventions such as vector con-
trol, and environmental management to better control
the Culex spp. vectors [28]. Thus, information on the
vector biting rates may be key for better insights into the
transmission dynamics and elimination in a geographic
region, especially in the endgame phase where there is
the risk of recrudescence, as highlighted in recent math-
ematical models [29, 30].
The NPELF may also consider the possibility and
feasibility of triple drug therapy, including ivermectin,
DEC and albendazole (IDA) and the protocols have
recently been released for field use [31, 32]. The high
effectiveness of this therapy, may shorten the duration
and cost of MDAs, especially in potential ‘hotspot’
areas, or where MDA coverage has been repeatedly
interrupted such as Mandalay, which had only three
MDAs over a 8 year period and showed areas of per-
sistent infection [33]. The IDA may also be useful for
areas with low, or lowered prevalence where trans-
mission appears difficult to ultimately interrupt [28].
However, measuring and modelling the impact of IDA
on filariasis prevalence will be crucial. Understanding
the barriers to high MDA coverage will also be im-
portant, and more in-depth studies in problem areas
should be undertaken [34, 35]. Further, it will be im-
portant for the NPELF to strengthen its response to
and recording of adverse reactions as this has been a
programme weakness to date.
The TAS in five districts confirms that transmission has
declined significantly in some areas of the country. How-
ever, as standard post-MDA surveillance activities scale up
over the next 5 years, the NPELF could be further
strengthened by training more personnel and increasing
the number of teams to support the activities on a more
full-time basis as other countries have done [7, 19]. Inte-
grating alternative methods of monitoring and evaluation
into the existing health system structure will also be
important to ensure that surveillance is sustainable long-
term, and sufficiently sensitive and targeted to find poten-
tial problem areas or hotspots of transmission [36, 37]. In
parallel, MMDP mapping and related activities, and add-
itional integrated post-TAS activities need be initiated and
could be conducted using new tools and field scenar-
ios [7, 38]. The districts with high burden of chronic dis-
ease and high baseline infection should be prioritized, and
the key activities integrated with health system.
Conclusions
This study highlights that the Myanmar NPELF has
made positive steps forward in the elimination of LF
with significant reductions in prevalence and the first
evidence of interrupting transmission. It will be im-
portant for the NPELF to maintain this momentum,
aim to maximize its capacity and draw on inter-
national stakeholder support to help meet the na-
tional and global goals of elimination.
Aye et al. Infectious Diseases of Poverty  (2018) 7:56 Page 9 of 11
Additional files
Additional file 1: Multilingual abstracts in the five official working
languages of the United Nations. (PDF 250 kb)
Additional file 2: Baseline Mf prevalence in district sentinel sites.
(DOCX 35 kb)
Additional file 3: Matrix of MDA in endemic districts from 2001 to
2014. (DOCX 37 kb)
Additional file 4: ICT Survey in school children in Tamu Township
District in 2008. (DOCX 23 kb)
Additional file 5: ICT Survey in school children in Katha District in 2008.
(DOCX 25 kb)
Additional file 6: ICT Survey in infant and school children from Kalay
District in 2008. (DOCX 22 kb)
Abbreviations
Ag: Antigenaemia; DEC: Diethylcarbamazine; EU: Evaluation unit;
ICT: Immuno-chromatographic test; IU: Implementation unit;
GIS: Geographical information system; GPELF: Global program to eliminate
lymphatic filariasis; LF: Lymphatic filariasis; MDA: Mass drug administration;
Mf: Microfilaria; MAM: Minimum adequate model; MoHS: Ministry of Health
and Sports; MMDP: Morbidity management and disability prevention;
NPELF: National Programme to Eliminate Lymphatic Filariasis;
TAS: Transmission assessment survey; WHO: World Health Organization
Acknowledgements
We are grateful to the children, parents, Head Masters, teachers, basic Health
Staff working in the relative Health Centers in the study communities, and to
the individuals, personnel from Central, State a/ Regional, District and
Township Vector Borne Disease Control teams, and the field research
assistants who helped in undertaking the programmatic work.
Funding
The LF programme activities were supported by the Ministry of Health and
Sports, and funds from the Centre for Neglected Tropical Diseases (CNTD),
Liverpool, UK through a grant from the Department for International
Development (DFID) and GlaxoSmithKline (GSK) for the elimination of
lymphatic filariasis.
Availability of data and materials
Please contact author for additional data requests.
Authors’ contributions
NNA and LAKH conceived the idea for the study. LAKH, KR and HB
conducted the formal data analysis and visualization. NNA, ZL, TWN and
KMM curated and organized the data. LAKH, KR, and NNA wrote the first
version of the manuscript. All authors contributed equally to the critical
review and editing of the final manuscript. All authors read and approved
the final manuscript.
Ethics approval and consent to participate
The LF programmatic MDA implementation, and surveillance surveys
conducted by the Ministry of Health, Myanmar are part of routine activities
and permit the use of oral consent. For TAS, additional approval from the
Ministry of Education, local authorities, and Headmasters of the selected
schools was obtained prior to the commencement of the surveys. All
parents were informed of the TAS activity and provided consent, and the
selected children were verbally informed of the procedures on the day of
the survey. Those who did not want to participate were excluded. Approval
was obtained from the Liverpool School of Tropical Medicine Research Ethics
Committee (Research Protocol 11.89R).
Competing interests
The authors declare that they have no competing interests.
Author details
1Ministry of Health and Sports, Department of Public Health, Nay Pyi Taw,
Myanmar. 2Tagore Nagar, Pondicherry, India. 3Department of Parasitology,
Centre for Neglected Tropical Diseases, Liverpool School of Tropical
Medicine, Liverpool, UK.
Received: 31 July 2017 Accepted: 5 April 2018
References
1. World Health Organization. Global programme to eliminate lymphatic
filariasis: progress report, 2015. Wkly. Epidemiol. Rec. 2016;91:73–88.
Available from: http://www.who.int/lymphatic_filariasis/resources/who_
wer9139/en/. Accessed 16 Mar 2018.
2. Ramaiah KD, Ottesen E a. Progress and impact of 13 years of the global
Programme to eliminate lymphatic Filariasis on reducing the burden of
filarial disease. PLoS Negl Trop Dis 2014;8:e3319. Available from: http://dx.
plos.org/10.1371/journal.pntd.0003319. Accessed 16 Mar 2018.
3. Dreyer G, Norões J, Figueredo-Silva J, Piessens WF. Pathogenesis of
lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitol
Today. 2000;16:544–8.
4. World Health Organization. Lymphatic filariasis: Managing morbidity and
preventing disability. Geneva; 2013. Available from: http://www.who.int/
lymphatic_filariasis/resources/9789241505291/en/. Accessed 16 Mar 2018.
5. Michael E, Bundy DAP, Grenfell BT. Re-assessing the global prevalence and
distribution of lymphatic filariasis. Parasitology. 1996;112:409–28.
6. Cano J, Rebollo MP, Golding N, Pullan RL, Crellen T, Soler A, et al. The global
distribution and transmission limits of lymphatic filariasis: past and present.
Parasit Vectors. 2014;7:466.
7. Dickson B, Graves P, McBride W. Lymphatic Filariasis in mainland Southeast
Asia: a systematic review and meta-analysis of prevalence and disease
burden. Trop Med Infect Dis. 2017;2:32.
8. World Health Organization. Regional Strategic Plan for Integrated Neglected
Tropical Diseases Control in South-East Asia Region, 2012-2016. New Delhi,
India, 9–10 August 2011; 2012 Available from: http://appssearowhoint/pds_
docs/B4867pdf?ua=1. Accessed 16 Mar 2018.
9. de Meillon B, Grab B, Sebastian A. Evaluation of Wuchereria bancrofti
infection in Culex pipiens fatigans in Rangoon, Burma. Bull World Health
Organ. 1967;36:91–100.
10. Sasa M. Human filariasis – a global survey of epidemiology and control.
Baltimore: University Park Press; 1976.
11. Research and Training in Tropical Diseases (TDR). Research on Rapid
Geographical Assessment of Bancrofti Filariasis. 1997. Report No.: Document
TDR/TDF/ComCT/98.2. Available from: http://apps.who.int/iris/handle/10665/
63960. Accessed 16 Mar 2018.
12. World Health Organization. Report on the mid-term assessment of
microfilaraemia reduction in sentinel sites of 13 countries of the Global
Programme to Eliminate Lymphatic Filariasis. Wkly. Epidemiol. Rec. 2004;79:
358–367. Available from: http://www.who.int/neglected_diseases/resources/
who_wer7940/en/. Accessed 16 Mar 2018.
13. World Health Organization. Global Programme to Eliminate Lymphatic
Filariasis: A Manual for National Elimination Programmes (Monitoring and
Epidemiological Assessment of Mass Drug Administration). Geneva; 2011.
Available from: http://www.who.int/lymphatic_filariasis/resources/
9789241501484/en/ Accessed 16 Mar 2018.
14. World Health Organization (WHO). Transmission Assessment Workshops.
Available from: http://apps.searo.who.int/PDS_DOCS/B4925.pdf and http://
www.wpro.who.int/mvp/meetings/docs/en/ Accessed 16 Mar 2018.
15. MIMU. Myanmar Information Management Unit. The 2014 Myanmar
population and housing census. 2014. Available from: http://themimu.info/
census-data. Accessed 16 Mar 2018.
16. Vector Borne Disease Control Program. VBDC Annual Report. The Republic
of the Union of Myanmar, Ministry of Health and Sports. 2014. Available
from: http://www.moh.gov.mm/. Accessed 16 Mar 2018.
17. Crawley M. The R Book. Chichester: Wiley; 2007.
18. Kyelem D, Biswas G, Bockarie MJ, Bradley MH, El-Setouhy M, Fischer PU,
et al. Determinants of success in national programs to eliminate lymphatic
filariasis: a perspective identifying essential elements and research needs.
Am J Trop Med Hyg. 2008;79:480–4.
19. Shamsuzzaman AKM, Haq R, Karim MJ, Azad MB, Mahmood ASMS, Khair A,
et al. The significant scale up and success of transmission assessment
surveys ‘TAS’ for endgame surveillance of lymphatic filariasis in Bangladesh:
one step closer to the elimination goal of 2020. PLoS Negl Trop Dis 2017;11:
Aye et al. Infectious Diseases of Poverty  (2018) 7:56 Page 10 of 11
e0005340. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC5302837/. Accessed 16 Mar 2018.
20. Dunn JC, Bettis AA, Wyine NY, Lwin AMM, Lwin ST, Su KK, et al. A cross-
sectional survey of soil-transmitted helminthiases in two Myanmar villages
receiving mass drug administration: epidemiology of infection with a focus
on adults. Parasit Vectors. 2017;10:374.
21. World Health Organization. Integrating neglected tropical diseases into
global health and development: fourth WHO report on neglected tropical
diseases. 2017. Available from: http://www.who.int/neglected_diseases/
resources/9789241565448/en/ Accessed 16 Mar 2018.
22. World Health Organization. Validation of elimination of lymphatic filariasis as
a public health problem. Geneva; 2017. Available from: http://www.who.int/
lymphatic_filariasis/resources/9789241511957/en/. Accessed 16 Mar 2018.
23. Risso-Gill I, McKee M, Coker R, Piot P, Legido-Quigley H. Health system
strengthening in Myanmar during political reforms: perspectives from
international agencies. Health Policy Plan. 2014;29:466–74.
24. Ramaiah KD, Das PK, Vanamail P, Pani SP. Impact of 10 years of
diethylcarbamazine and ivermectin mass administration on infection and
transmission of lymphatic filariasis. Trans R Soc Trop Med Hyg 2007;101:555–63.
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239120/.
Accessed 16 Mar 2018.
25. Swaminathan S, Perumal V, Adinarayanan S, Kaliannagounder K, Rengachari
R, Purushothaman J. Epidemiological assessment of eight rounds of mass
drug administration for lymphatic filariasis in India: implications for
monitoring and evaluation. de Silva N. PLoS Negl Trop Dis. 2012;6:e1926.
26. El-Setouhy M, Abd Elaziz KM, Helmy H, Farid HA, Kamal HA, Ramzy
RMR, et al. The effect of compliance on the impact of mass drug
administration for elimination of lymphatic filariasis in Egypt. Am J Trop
Med Hyg. 2007;77:1069–73.
27. Ojha CR, Joshi B, Kc KP, Dumre SP, Yogi KK, Bhatta B, et al. Impact of mass
drug administration for elimination of lymphatic filariasis in Nepal. PLoS
Negl Tro Dis. 2017;11:e0005788.
28. Irvine MA, Reimer LJ, Njenga SM, Gunawardena S, Kelly-Hope L, Bockarie M,
et al. Modelling strategies to break transmission of lymphatic filariasis
-aggregation, adherence and vector competence greatly alter elimination.
Parasit Vectors. 2015;8:547.
29. Singh BK, Michael E. Bayesian calibration of simulation models for
supporting management of the elimination of the macroparasitic disease,
lymphatic Filariasis. Parasit Vectors. 2015;8:522.
30. Michael E, Singh BK. Heterogeneous dynamics, robustness/fragility trade-
offs, and the eradication of the macroparasitic disease, lymphatic filariasis.
BMC Med. 2016;14:14. Available from:
31. Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, et al. Efficacy,
safety, and pharmacokinetics of Coadministered Diethylcarbamazine,
Albendazole, and Ivermectin for treatment of Bancroftian Filariasis. Clin
Infect Dis. 2016;62:334–41.
32. World Health Organization. Guideline: alternative mass drug administration
regimens to eliminate lymphatic filariasis. Geneva; 2017. Available from:
http://apps.who.int/iris/handle/10665/259381 Accessed 16 Mar 2018.
33. Dickson B, Graves P, Aye N, Nwe T, Win S, Douglass J, et al. The prevalence
of lymphatic filariasis related hydrocele, lymphedema and infection in
Mandalay region, Myanmar. In: American Society of Tropical Medicine and
Hygiene. 64th annual meeting. Philadelphia; 2015. http://www.astmh.org/
annual-meeting/past-meetings.
34. Krentel A, Gyapong M, Mallya S, Boadu NY, Amuyunzu-Nyamongo M,
Stephens M, et al. Review of the factors influencing the motivation of
community drug distributors towards the control and elimination of
neglected tropical diseases (NTDs). PLoS Negl Trop Dis. 2017;11:e0006065.
35. Krentel A, Fischer PU, Weil GJ. A review of factors that influence individual
compliance with mass drug administration for elimination of lymphatic
filariasis. PLoS Negl Trop Dis. 2013;7:e2447.
36. Baker MC, Mathieu E, Fleming FM, Deming M, King JD, Garba A, et al.
Mapping, monitoring, and surveillance of neglected tropical diseases:
towards a policy framework. Lancet. 2010;375:231–8.
37. Hollingsworth T, Langley I, Nokes D, Macpherson EE, McGivern G, Adams ER,
et al. Infectious disease and health systems modelling for local decision
making to control neglected tropical diseases. BMC Proc. 2015;9:S6.
Available from: http://www.biomedcentral.com/1753-6561/9/S10/S6.
Accessed 16 Mar 2018.
38. Mableson H, Martindale S, Stanton MC, Mackenzie C, Kelly-Hope LA.
Community-based field implementation scenarios of an SMS reporting tool
for lymphatic filariasis case estimates in Africa and Asia. mHealth. 2016;3:28.
Aye et al. Infectious Diseases of Poverty  (2018) 7:56 Page 11 of 11
